Anticancer activity of Schiff base-Poloxamer P85 combination against kidney cancer

Dogan, A | Demirci, S | Telci, D | Canikyan, S | Kongur, M | Dede, B | Şahin, Fikrettin

Article | 2018 | INTERNATIONAL UROLOGY AND NEPHROLOGY50 ( 2 ) , pp.247 - 255

Renal cell carcinoma (RCC) accounts for approximately 80% of the primary renal cancers, and current treatment strategies are not sufficient to provide a certain solution. Since there are not many treatment options, interest in discovery of alternative drugs has increased. In the current study, anticancer activity of a novel heterodinuclear Cu(II)-Mn(II) complex (Schiff base-SB) in combination with poly(ethylene oxide) and poly(propylene oxide) block copolymer (pluronic) P85 was tested against RCC. Cell viability, apoptosis and gene expression analysis were conducted in vitro by using Renca cells. The results revealed that the SB-P85 . . . combination decreased cell proliferation by increasing the apoptotic gene expressions and apoptosis. Renca-injected BALB/c mice were used to mimic early stage of RCC model. Treatment with SB-P85 combination suppressed tumor formation and growth compared to baseline. Overall, SB-P85 showed promising anticancer activity against RCC in vitro and in vivo Daha fazlası Daha az

Bronchial Artery Embolization with Large Sized (700-900 A mu m) Tris-acryl Microspheres (Embosphere) for Massive Hemoptysis: Long-Term Results (Clinical Research)

Kucukay, F | Topcuoglu, OM | Alpar, A | Altay, CM | Kucukay, MB | Ozbulbul, NI

Article | 2018 | CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY41 ( 2 ) , pp.225 - 230

To investigate the safety, efficacy and long-term results of bronchial artery embolization with microsphere particles (Embosphere(A (R)) Microspheres, BioSphere Medical, Rockland, MA) 700-900 A mu m in size for massive hemoptysis. One hundred and seventy-four patients (94 female, 80 male; mean age 39.4 +/- 5.7) who had bronchial artery embolization for massive hemoptysis between January 2010 and October 2015 were incorporated in the study. Patients had hemoptysis with a mean volume of 525 +/- 150 mL (median 500 mL, range 300-1200 mL) over a 24-h period. Underlying pathologies included bronchial artery hypertrophy due to bronchiectas . . .is (56.3% [98/174]), lung cancer (29.9% [52/174]), tuberculosis (10.3% [18/174]) and the rest remained idiopathic (3.4% [6/174]). Mean bronchial artery diameter before the intervention was 3.8 +/- 1.5 mm (median 4 mm, range 3.1-7.5 mm). Median follow-up period was 56 months (range 10-82 months). Primary objectives were the technical and clinical success. Technical success was 100%. Clinical success for preventing massive hemoptysis was 91.9% (160/174). There was no procedure-related mortality or morbidities. Minor complications such as chest pain were observed in nine patients (5.0%). Recurrent hemoptysis (8.1%) was observed within 6 months in 14 patients, ten of whom were treated with a second embolization session and the remaining four with a total of three embolization sessions. Bronchial artery embolization for massive hemoptysis with Embosphere particles 700-900 A mu m in size is a safe and effective method with high technical and clinical success rates. Long-term results are excellent Daha fazlası Daha az

Mutations in YIPF5 are a novel cause of neonatal diabetes, highlighting the critical role of endoplasmic reticulum-to-Golgi trafficking in human beta cell survival

De Franco, E | Lytrivi, M | Patel, K | Igoillo-Esteve, M | Wakeling, M | Haliloglu, B | Hattersley, AT

Conference Object | 2018 | DIABETOLOGIA61 , pp.225 - 230

Determination of Radiation Dose in 177Lu-DOTATATE Treatment with 99m-Tc-HYNICTATE Scintigraphy

Yeyin, N | Toklu, T | Aygun, A | Karayel, E | Pehlivanoglu, H | Demirci, E | Kabasakal, L


Can SUVmax Values of 68Ga-PSMA PET/CT scan Predict the Clinically Significant Prostate Cancer

Sahin, OE | Akgun, E | Demirci, E | Gultekin, M | Doganca, T | Tuna, M | Kabasakal, L


6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.